Curis traded at $1.35 this Friday September 4th, decreasing $0.02 or 1.46 percent since the previous trading session. Looking back, over the last four weeks, Curis lost 71.40 percent. Over the last 12 months, its price fell by 96.05 percent. Looking ahead, we forecast Curis to be priced at 1.46 by the end of this quarter and at 1.37 in one year, according to Trading Economics global macro models projections and analysts expectations.
Curis, Inc. is a biotechnology company focused on the development of therapeutics for the treatment of cancer. The Company’s drug candidates include CA-4948 and CI-8993. CA-4948 is an orally available small-molecule inhibitor of Interleukin-I receptor-associated kinase 4, which is undergoing testing in a Phase I open-label dose escalating clinical trial in patients with non-Hodgkin lymphomas. It is also conducting a Phase I open-label, single-arm dose escalating trial in patients with acute myeloid leukemia, and myelodysplastic syndromes. CI-8993 is a monoclonal antibody designed to antagonize the V-domain Ig suppressor of the T cell activation signaling pathway. The Company initiated a Phase Ia/Ib trial of CI-8993 in patients with solid tumors. The Company’s products pipeline includes Fimepinostat, CA-170, CA-327, and PD1/TIM3 Program.